Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers

Trial Profile

A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs SPR 741 (Primary) ; Aztreonam; Ceftazidime; Tazobactam
  • Indications Gram-negative infections
  • Focus Pharmacokinetics
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 28 Aug 2018 According to a Spero Therapeutics media release, the company expects that data from a phase 1 clinical trial of SPR206 (298950) together with the data from this completed trial (SPR741) will enable the selection of a lead candidate from the Potentiator Platform to move forward into late stage development.
    • 23 May 2018 Results presented in a Spero Therapeutics media release.
    • 02 Apr 2018 According to a Spero Therapeutics media release, company plans to annouce a top-line data from this trial in second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top